Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pílulas de Lussen is a traditional Brazilian oral combination therapy developed by Laboratórios Osório De Moraes for the symptomatic relief of dysuria and urinary tract discomfort. The formulation typically contains methylene blue and acriflavine hydrochloride, which function as urinary antiseptics. Methylene blue acts as a mild antiseptic and redox agent, while acriflavine is a topical and urinary antiseptic known to intercalate into microbial DNA. The drug has been evaluated in Phase III clinical trials (such as NCT01441011) to assess its efficacy and safety compared to phenazopyridine (Pyridium) for the control of painful urination in adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pílulas de Lussen.